Search
Kymera Therapeutics Inc
KYMRAdd to Watchlist
116.850USD
+7.530+6.89%
Market hours （ET）Quotes delayed by 15 min
9.60BMarket Cap
LossP/E TTM
Financial Health
Currency: USD Updated: 2026-06-29 The current financial score of Kymera Therapeutics Inc is 8.79, ranking 28 out of 387 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 34.37M, representing a year-over-year increase of 55.50%, while its net profit experienced a year-over-year increase of 5.57%.
Financials
7.45
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.67
Total revenue
Operating profit
Total assets
SG&A
Relevant data have not been disclosed by the company yet.
Operational Efficiency
10.00
Cash flow from operating activities
Income after tax
Relevant data have not been disclosed by the company yet.
Growth Potential
10.00
Cash flow from operating activities
Total revenue
Relevant data have not been disclosed by the company yet.
Shareholder Returns
7.83
Free cash flow
Relevant data have not been disclosed by the company yet.
